Evidence map›Paper›PMID 39062751›Full record

ArticleInternational journal of molecular sciences2024

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.

Donato Michele Cosi, Cristina Fragale, Chiara Magri, Aldo Carnevale, Antonella Ciancetta, Massimo Guidoboni, Massimo Negrini, Giuseppe Bronte, Luana Calabrò

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Donato Michele CosiDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Cristina FragaleDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Chiara MagriDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Aldo CarnevaleDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-8191-6042
Antonella CiancettaDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-7612-2050
Massimo GuidoboniDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Massimo NegriniDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Giuseppe BronteDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Luana CalabròDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-3044-0889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Third-generation tyrosine kinase inhibitors are the first-line gold standard in treating advanced non-small-cell lung cancer bearing common

Indexed as

AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungErbB ReceptorsExonsLung NeoplasmsMutationProtein Kinase InhibitorsAgedAntineoplastic AgentsFemaleHumansIndolesMaleMiddle AgedPyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinescompound mutationepidermal growth factor receptornon-small-cell lung cancertyrosine kinase inhibitor

Identifiers

PMID39062751
PMCPMC11277248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.